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Oral Presentations 33patient is given tape to practice the treatment position and im-
mobilization at home. The children enjoy the ‘‘hands on’’ expe-
rience and the opportunity to show others what they have
learned. Our center has successfully treated 4 children (ages
2.6 years – 4.6 years) over the past 2 years without GA. This
has allowed the children to eat ad lib, minimized their time in
clinic, and improved their overall quality of life. In addition,
it is estimated that $55,000 per patient is saved by treating
without GA. There is scant information in the medical litera-
ture about this approach. We plan to continue to study it’s fea-
sibility over the next 2 years.81
TIME IS MONEY!: COST ANALYSIS OF NURSING SALARY EXPENDITURE
AND TIME SAVINGS BY UTILIZING THE BIOPATCH DRESSING FOR CEN-
TRAL VENOUS CATHETERS ON AN INPATIENT BONE MARROW TRANS-
PLANT UNIT
Cunningham, B., Devine, D., Harvey, K. St. Francis Hospital and Health
Centers, Beech Grove, IN; Indiana Blood and Marrow Transplantation,
Beech Grove, IN
Background: The use of a BIOPATCH Dressing for central ve-
nous catheters (CVC) has proven to reduce catheter-related blood-
stream infections (CRBI) and extended patient stays in the Bone
Marrow Transplant Unit (BMTU), University of Wisconsin Hos-
pital. The use of the BIOPATCH Dressing has decreased the num-
ber of CVC dressing changes performed each week by BMTU
nurses at St. Francis Hospital. Nurses gained additional time to
perform more nursing tasks such as patient education and psycho-
social support for patients. Existing literature offered no informa-
tion about the savings in nursing time and salary expenditure by
utilizing a BIOPATCH Dressing for CVC. This study examined
monetary savings for nursing time and salary expenditure by using
the BIOPATCH Dressing.
Method: A data collection tool was designed to track the date
of each CVC dressing change utilizing the BIOPATCH Dressing
from 3/2007 to 2/2008. Other data collected included the reason
for the dressing change and a CVC exit site skin assessment. A
mean time of 10 minutes required to change a CVC dressing
was calculated using observational data from the skill perfor-
mance of 10 BMTU nurses. Information provided by unit man-
agement disclosed that the mean hourly rate for nursing salary
was $30.00.
Results: Analysis of patient data (N 5 71; 1494 hospital days)
revealed the number of required CVC dressing changes under
the old BMTU Policy (M,W,F) would total 640. By using a BIO-
PATCH Dressing, the number of dressing changes under the
amended Policy (1 day/week) totaled 225 representing
a reduction of 65% or 415 dressing changes. Nursing salary ex-
penditure for 640 CVC dressing changes would total
$3,200.00. Nursing salary expenditure for 225 dressing changes
totaled $1,065.00 representing a 66% reduction and savings of
$2,135.00. Nursing time required to complete 640 dressing
changes was 106.5 hours. Nursing time required to complete
225 dressing changes totaled 35.5 hours representing a 66%
reduction and savings of 71 hours.
Conclusion: Study data validated changes in unit policy regarding
CVC dressing changes. By eliminating 2 dressing changes a week,
nurses gain additional time to address patient needs which has in-
creased job satisfaction. The decrease in nursing salary expenditure
was shown to be significant. More research is needed to determine
if money saved can result in hiring of more nurses or changes in
nurse:patient ratios.82
NURSING CARE OF THE BONE MARROW TRANSPLANT PATIENT WITH
HEMORRHAGIC CYSTITIS
Eron, B., Talbert, G., Shea, T. UNC Hospital, Chapel Hill, NC
Hemorrhagic cystitis is a complication that can occur after an
allogeneic stem cell transplant. Painful bladder spasms, urinary
bleeding, clots and frequency are symptoms that patients oftenpresent with during episodes of hemorrhagic cystitis. Savon
(2007) states that hemorrhagic cystitis is caused by BK virus, a hu-
man polyomavirus acquired in childhood, which remains latent in
the genitourinary tract throughout life. Arthur (1986) noted an as-
sociation between activation of BK virus and hemorrhagic cystitis
in allogeneic stem cell recipients. In an effort to reduce viral load,
weekly infusions of cidofovir are often used until the BK copies
are detected less often, prednisone dose is reduced and immuno-
suppressant therapy is being tapered. Recently in an attempt at
symptom relief, weekly intravesicular (bladder) cidofovir infusions
have been used with some success. The bladder infusions of cido-
fovir are specifically for relief of the discomfort related to the
hemorrhagic cystitis and do not treat the BK virus. Patients’
most frequent complaint associated with hemorrhagic cystitis is
pain. The cidofovir bladder infusion is designed to coat the inside
of the bladder with a dilute solution of cidofovir. This is achieved
by instilling the solution and clamping the bladder for 45 minutes
to one hour. Encouraging the patient to void prior to the instilla-
tion did reduce some discomfort. Each patient’s pain tolerance is
different and determining the appropriate amount of pain medica-
tion to alleviate the discomfort of instilling a foley catheter, med-
ication, clamping, and tolerating the time of the treatment were
all significant challenges. Clearly addressing the challenges of
the procedure and enlisting the patient’s assistance in selecting
the amount and timing of the pain medication gave the patient
some degree of control in a difficult situation. The bladder infu-
sions are routinely preformed on a weekly outpatient basis. Pa-
tients continue until they have an abatement of symptoms;
which has not shown to be related to the number of BK copies
in the urine or serum BK virus. The purpose of this poster is to
describe the unique aspects of nursing care for the BMT patient
receiving intravesicular cidofovir for the management of BK virus
associated cystitis.PHARMACY ORAL
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IMPACT OF A PHARMACIST IN THE OUTPATIENT ALLOGENEIC STEM
CELL TRANSPLANT CLINIC
Burzynski, J.A.1, Craver, L.F.2, Geerdes, P.A.1, Perreault, S.K.1,
Litzow, M.R.1, Hogan, W.J.1, Elliott, M.A.1, Wolf, R.C.1 1Mayo Clinic,
Rochester, MN; 2Drake University, Des Moines, IA
Background: Although it has demonstrated benefit in cancer
patients, pharmacist involvement in direct patient care of alloge-
neic stem cell transplant (SCT) patients has not been described.
The 2009 National Patient Safety Goals from the Joint Commis-
sion emphasize the importance of accurate and complete medica-
tion lists (including drug, dose, route, and frequency) across the
continuum of care to reduce adverse drug events. We hypothesize
that including a pharmacist in the care of patients undergoing al-
logeneic SCT will improve medication list accuracy and improve
pharmaceutical care.
Methods: Allogeneic SCT patients commenced scheduled phar-
macist appointments at Mayo Clinic on 5/5/08 prior to their physi-
cian visit to complete medication reconciliation and provide
pharmaceutical care. Allogeneic SCT patients were included if
they had a pharmacist appointment in the SCT clinic between 5/5/
08 and 10/1/08. Patients were excluded if they refused consent for
use of their medical records for research or had not been evaluated
by a Mayo Clinic physician for more than 1 year. Retrospective
data was collected to analyze trends in medication list accuracy.
Mean medication list omissions were compared by Wilcoxon rank-
sum tests and McNemar’s test was used to compare error-free med-
ication lists. Pharmaceutical care recommendations and outcomes
(drug interaction management, dose adjustment in organ dysfunc-
tion, formulation changes to improve adherence or efficacy, etc.)
were recorded.
Results: A pharmacist met with 90 patients between 5/5/08 and
10/1/08 prior to each physician visit, totaling 410 patient visits
during 105 clinic days. Three patients were excluded; consent re-
fused (n 5 2) and no physician visit at Mayo Clinic during past
year (n 5 1). Patients had a range of 3 to 49 medications (median
34 Oral Presentations17). 72% of patients had at least 1 medication omitted from their
list at their first pharmacist visit. 367 pharmaceutical care recom-
mendations were made on 76 patients, with 72% of recommenda-
tions accepted. The most frequent recommendations included
osteoporosis prevention/management (n 5 51), calcineurin inhib-
itor dose adjustment (n 5 43), pneumocystis prophylaxis (n5 26),
electrolyte replacement (n 5 25), and antiviral prophylaxis/treat-
ment (n 5 20). 220 medications were identified as requiring
a new written prescription.
Conclusion: Pharmacist involvement in the allogeneic stem cell
transplant clinic has improved medication list accuracy and pharma-
ceutical care of patients.Improvement in Medication List Accuracy
Medication
List
Visit 1
N573
Visit 2
N573 p value
Visit 2
N553
Visit 3
N553 p value
Medication
Omissions
(Mean)
11.1% 5% \0.0001 4.8% 2.6% 0.04
Prescription
Medication
Omissions
(Mean)
5.7% 2.8% 0.001 2.8% 1.4% 0.101
Dose Omission/
Errors (Mean)
8.6% 4.1% \0.0001 4.5% 1.9% 0.006
Schedule Omission/
Errors (Mean)
4.3% 1.1% \0.0001 1.1% 1.1% 0.988
Route Omission/
Errors (Mean)
15.4% 3.1% \0.0001 3.9% 1.8% 0.08
Patients with
Error-Free
Medication List
2.7% 31.5% \0.0001 28.3% 43.4% 0.08
*Visit 2 percentages are slightly different as there are fewer patients with
at least 3 visits.84
MEDACTIONPLAN.COM AS A TOOL FOR PATIENT EDUCATION AND MED-
ICATION MANAGEMENT IN THE BLOOD AND MARROW TRANSPLANT
SETTING
Chuang, W.1, Pineiro, M.J.2,1, Ginsburg, A.1, Reyes, A.1, Ueng, C.1,
Matta, C.1, Taschek, M.2,1, Agura, E.A.1,2, Berryman, R.B.1,2,
Pineiro, L.A.1,2, Vance, E.A.1,2, Fay, J.W.1,2 1Baylor University Medical
Center, Dallas, TX; 2Texas Oncology - Charles A. Sammons Cancer Cen-
ter, Dallas, TX
Baylor University Medical Center performs approximately 200
Blood and Marrow transplants annually in the inpatient and out-
patient settings. The medication regimens prescribed for these
patients at discharge are complex, confusing, and often prove
overwhelming to patients during the transplant process. In our
program, pharmacy staff works in conjunction with the physi-
cians to provide medication education and teaching to transplant
patients. We began using MedActionPlan.com, a free web-based
tool that allows for the creation of personalized treatment plans
for patients and saves their records in a program specific data-
base. Each plan includes images of the medications prescribed,
instructions of use, abbreviated drug information for each med-
ication as well as a medication schedule checklist for patient use.
This checklist may be used to record adherence, upcoming ap-
pointments or other relevant medical information. Plans may
be customized to fit individual patient needs and have the option
to be translated into Spanish. All medication plans are accessible
from any computer by a user specific log-on and password.
MedActionPlan.com is secure, and meets all HIPPA require-
ments and Joint Commission’s goals for improving patient safety
and education for medication therapy. The web-based program
also contains an export function, allowing schedules to be sent
directly to patients for their medication managment. These
schedules can be customized into regular-print, large-font or
wallet-sized versions depending on patient-specific needs. In ad-
dition to enhancing communication between the inpatient andoutpatient facilities, MedActionPlan.com has empowered our pa-
tients and their caregivers to be proactive participants in their
healthcare program. Patients are able to quickly refer to a centralized
and comprehensive medication profile which allows for significantly
improved understanding of, and ultimately, compliance with com-
plex medication regimens. MedActionPlan.com has proved to be
a valuable resource and has both enhanced the quality of patient ed-
ucation in our transplant program and improved the continuity of
care between inpatient and outpatient settings.85
DEVELOPMENT AND COMPARISON OF LIMITED SAMPLING STRATEGIES
FOR PHARMACOKINETICALLY-GUIDED HIGH-DOSE, INTRAVENOUS BU-
SULFAN
Kazerooni, R.1, Madden, T.1, McAdams, P.2, de Lima, M.2, Jones, R.B.2,
Kebriaei, P.2, Champlin, R.2, Andersson, B.2 1University of Texas M.D.
Anderson Cancer Center, Houston, TX; 2University of Texas M.D. An-
derson Cancer Center, Houston, TX
High-dose, intravenous (IV) busulfan (Bu) is widely used in
stem cell transplantation conditioning regimens, and is favored
for its pharmacokinetic (PK) predictability and complete dose
assurance. A one-compartment, first-order elimination PK
model adequately describes the behavior of Bu following IV ad-
ministration, allowing for prospective targeting of a specific sys-
temic exposure (AUC) to preparative regimens for each
individual patient. Traditional ‘full’ sampling commonly utilizes
9 to11 samples over 10–16 hours, following a 2–3 hr drug infu-
sion , to calculate Bu plasma clearance (ClT). We hypothesized
that 4–5 samples drawn at selected times during the elimination
phase would be sufficiently accurate to calculate ClT. Here we
present a limited sampling strategy (LSS) as basis for the valida-
tion of a Bayesian method that optimizes such sample schema.
Decreasing the number of timepoints would reduce the analyt-
ical, logistical efforts while cost containing. We analyzed Bu PK
in 87 patients to develop a LSS method. From 42 patients, we
collected and analyzed the full sampling data from the 3rd of 4
daily doses and compared the AUC obtained , to that obtained
when using a 5-point LSS. For a 5-point LSS (5 min before
EOI, 4, 6, 10, and 12 hour), the mean daily AUC calculation
was 0.2% lower (5132 vs. 5142 mM-min) with like coefficient
of variation (CV, 18.8% each), compared to the full method.
In a follow-up study, using an additional 11 consecutive pa-
tients, we investigated whether a 4-point LSS (deleting the 5
min prior to the EOI timepoint) was significantly different in
determination of AUC; the 4-point LSS yielded average AUC
that was 3.2% . the 5 point method (985 vs. 954 mM-min)
with variability that was slightly . the 5-point method (CV,
9.6% vs. 13.6%). To determine whether a 4- or 5-point LSS
would be preferable, data on the 1st dose in an additional 45 pa-
tients from an alternative arm of this study were analyzed. The
AUC based on full sampling was then compared with the AUC
from both 5- and 4-point LSS, resulting in AUC differences of
0.3% and 0.6% (6129 vs. 6108 and 6090 mM-min) with nearly
identical variability. The calculated AUC and other PK param-
eters from the 4- and 5-point LSS did not vary significantly
from full method, but greater variability was observed with
the 4-point method. We conclude that prospective validation
of a LSS is warranted and ongoing; demonstrating that 5-sample
LSS is favored for clinical therapeutic dose guidance.86
FAMCICLOVIR PROPHYLAXIS OF VARICELLA ZOSTER VIRUS REACTIVA-
TION IN CHILDREN AFTER HEMATOPOEITIC STEM CELL TRANSPLANTA-
TION
Charbonneau-Allard, A.-M., Therrien, R. UHC Ste-Justine, Montreal,
QC, Canada
Background: The usual varicella zoster virus (VZV) reactiva-
tion prophylaxis used in adults after hematopoietic stem cell
transplantation (HSCT) is oral acyclovir. In our institution, fam-
ciclovir was chosen over acyclovir because of fewer daily doses
